Pipeline

Core Global Development Pipeline of ONO

Oncology

As of 24 Jan, 2024

Product Name Mechanism Target Disease Development Stage Country /
Region
Licensor
1 2 3 Filing Approval
ONO-4059 BTK inhibitor Primary central nervous system lymphoma           JP・KR・TW In-house
          US
Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma           JP
ONO-7475 Axl/Mer inhibitor Pancreatic cancer ★           JP In-house
EGFR mutation-positive non-small cell lung cancer           JP
ONO-4685 PD-1 x CD3 bispecific antibody T-cell lymphoma           US In-house
ONO-4578 PG receptor (EP4) antagonist Gastric cancer ★           JP・KR・TW In-house
Colorectal cancer ★           JP
Pancreatic cancer ★           JP
Non-small cell lung cancer ★           JP
Hormone receptor-positive, HER2-negative breast cancer           JP
ONO-7914 STING agonist Solid tumor ★           JP In-house
ONO-7018 MALT1 Inhibitor Non-Hodgkin lymphoma, Chronic lymphocytic leukemia           US Chordia
ONO-8250 iPSC-derived HER2 CAR T-cell therapy HER2-expressing Solid tumor           US Fate

★Combination with Nivolumab

Other than oncology

As of 24 Jan, 2024

Product Name Mechanism Target Disease Development Stage Country /
Region
Licensor
1 2 3 Filing Approval
ONO-4059 BTK inhibitor Pemphigus           JP In-house
ONO-2910 Enhancement of Schwann cell differentiation Diabetic polyneuropathy           JP In-house
Chemotherapy-Induced Peripheral Neuropathy           JP In-house
ONO-4685 PD-1 x CD3 bispecific antibody Autoimmune disease           JP・EU In-house
ONO-2808 S1P5 receptor agonist Multiple System Atrophy           US In-house
ONO-2020 Epigenetic Regulation Neurodegenerative disease           US In-house
ONO-1110 Endocannabinoid regulation Pain           JP In-house